Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Cleantech Comes of Age

Related Content

How Generative AI Is Changing the Game for Deal Lawyers (Legaltech News)

Supreme Court Clarifies Scope of SEC’s Disgorgement Authority

FinCEN Issues Joint Advisory on Non-Work Authorized Populations and Their Employers and Risks to the Integrity of the US Financial System

SEC Proposes Rescission of Climate-Related Disclosure Rules

Getting Traction in European Defence

White House Issues Executive Order to “Restore Integrity” to America’s Financial System

SEC Proposes Significant Changes to the Registered Offering Framework

CFPB Narrows Small Business Lending Rule

Goodwin Advised the Sellers and Cerbair’s Management in Connection With Its Acquisition by Latour Capital

Goodwin Advises Roku on $22 Billion Acquisition by FOX Corporation

Goodwin Advises Sleep Country Canada on Agreement to Acquire Sleep Number

Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

Strategic M&A for Deep Tech (2026 Deep Tech Report)

Goodwin Guides Arlington Capital Partners on $1.45 Billion Sale of Riverpoint Medical to Novanta

Goodwin Strengthens Life Sciences Public M&A Bench With Partner Richard Schwartz

Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Mergers & Acquisitions